Certara® and Paidion Research, announced a new partnership to address the challenges inherent in pediatric drug development.
Certara®, a global biosimulation technology-enabled drug development company, and Paidion Research, a pediatric clinical research organization (CRO), announced a new partnership to address the challenges inherent in pediatric drug development including safe and effective dose or dose ranges and the conduct of trials. The partnership joins together Certara’s Simcyp® Pediatric PBPK simulator to inform the dose selections, with Paidon’s neonatal and pediatric intensive care unit and pediatric clinical site networks and clinical trials experience.
